Preferred Label : Lenacapavir;
UNII : A9A0O6FB4H;
InChIKey : BRYXUCLEHAUSDY-WEWMWRJBSA-N;
CAS number : 2189684-44-2;
NCI Metathesaurus CUI : CL1411928;
Origin ID : C174616;
UMLS CUI : C5244461;
Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
https://www.has-sante.fr/jcms/p_3390497/fr/sunlenca-lenacapavir-vih
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Lenacapavir
lenacapavir
anti-hiv agents
HIV-1
drug therapy, combination
hiv infections
drug resistance, multiple, viral
multiresistant HIV-1 infection
administration, oral
injections, subcutaneous
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Lenacapavir
Lenacapavir
lenacapavir
drug approval
europe
anti-hiv agents
anti-hiv agents
drug therapy, combination
hiv infections
adult
HIV-1
acquired immunodeficiency syndrome
administration, oral
injections, subcutaneous
product surveillance, postmarketing
multiresistant HIV-1 infection
aged
drug interactions
pregnancy
breast feeding
capsid proteins
drug evaluation, preclinical
---
https://ansm.sante.fr/tableau-acces-derogatoire/lenacapavir
2022
false
false
false
France
French
drug information
treatment outcome
insurance, health, reimbursement
anti-hiv agents
Lenacapavir
lenacapavir
adult
hiv infections
HIV-1
drug therapy, combination
multiresistant HIV-1 infection
administration, oral
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3392767/fr/sunlenca-lenacapavir-sodique-vih1-multiresistante-aux-medicaments
2022
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
antiviral agents
Lenacapavir
Lenacapavir Sodium
injections, subcutaneous
administration, oral
lenacapavir
drug therapy, combination
adult
hiv infections
HIV-1
drug resistance, multiple, viral
multiresistant HIV-1 infection
---
https://www.cadth.ca/fr/lenacapavir
2022
false
false
false
Canada
French
insurance, health, reimbursement
canada
drug evaluation
Lenacapavir
drug therapy, combination
hiv infections
adult
HIV-1
---
